- Home
- AGI vs BMRN Comparison
AGI vs BMRN Comparison
Compare AGI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGI | BMRN |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | Canada | United States |
| Employees | 2402 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.3B |
| IPO Year | 2002 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AGI | BMRN |
|---|---|---|
| Price | $31.71 | $55.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 28 |
| Target Price | $40.67 | ★ $91.04 |
| AVG Volume (30 Days) | ★ 3.3M | 2.6M |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $27.91 | $20.16 |
| Revenue Next Year | $19.76 | $15.17 |
| P/E Ratio | ★ $34.21 | $408.07 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $26.92 | $49.26 |
| 52 Week High | $55.41 | $70.98 |
Technical Indicators
Market Signals| Indicator | AGI | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 44.01 |
| Support Level | $29.84 | $53.85 |
| Resistance Level | $32.18 | $57.76 |
| Average True Range (ATR) | 1.12 | 1.81 |
| MACD | 0.20 | 0.27 |
| Stochastic Oscillator | 78.59 | 48.79 |
Price Performance
Historical ComparisonAbout AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has three operating segments being Young-Davidson, Island Gold District's operation operates in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Island Gold District mines.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.